Wanbury Ltd (WANBURY) — FY26 Annual Report | 31 August 2026 (2 announcements)

Wanbury Ltd's 2025-26 Annual Report and 38th AGM notice highlight a 10.7% net profit of [amount context mismatch] crores, no dividend, re-appointment of Whole-time Director Mohan Kumar Rayana with Rs 3 crore fixed remuneration and up to 4% performance-linked bonus, and successful regulatory audits (USFDA, ANVISA, TGA). The company resolved SEBI compliance gaps with Rs 1.38 lakh in fines paid, appointed independent directors, and implemented SAP S/4HANA. Key risks include regulatory penalties and foreign exchange exposure, while growth focuses on API expansion and new product launches like C-RED.

Wanbury Ltd's 2025-26 Annual Report shows revenue of ₹65,120.54 lakhs and net profit of ₹6,613.47 lakhs, with no dividends recommended. The AGM on 24 September 2026 will re-elect Whole-time Director Mohan Kumar Rayana beyond age 70 for 5 years at Rs 3 crore fixed pay plus 4% profit-linked bonus, capped at Rs 5 crore total. Shareholders must dematerialize shares via CDSL/NSDL for e-voting; 3,38,465 shares were transferred to IEPF for unclaimed dividends. Penalties totaling [amount not verified] were paid for SEBI compliance lapses in board composition and committee formation, later resolved. Energy conservation projects saved Rs 38.9 lakhs with Rs 537 lakhs investment. The company faces risks from competition, regulatory pressures, and foreign exchange volatility despite strong market shares in Metformin (10%) and Sertraline (30%).